8-K: Mural Oncology Acquisition Complete, Delists from Nasdaq

Mural Oncology plc has completed its acquisition by XOMA Royalty Corporation subsidiary, XRA 5 Corp., with shareholders receiving $2.035 per share in cash.

Summary

• Mural Oncology plc (Mural) has been acquired by XRA 5 Corp. (Sub), a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA Royalty).
• The acquisition was completed via an Irish High Court sanctioned scheme of arrangement, which became effective on December 5, 2025.
• Each outstanding ordinary share of Mural was acquired for $2.035 in cash.
• Options and restricted stock units were cancelled and converted into cash rights based on the $2.035 per share consideration, with options having an exercise price equal to or greater than $2.035 cancelled without consideration.
• Mural's ordinary shares were delisted from The Nasdaq Global Market effective before the opening of trading on December 5, 2025.
• Mural intends to file Form 15 with the SEC to suspend its reporting obligations.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive for shareholders who received the agreed-upon cash consideration. The successful completion of the acquisition provides certainty. However, the delisting and cessation of public reporting are negative for market transparency and liquidity for former shareholders.

Positives

• Successful completion of the acquisition provides a definitive cash value of $2.035 per share to Mural shareholders.
• The transaction was funded by XOMA Royalty with cash on hand, indicating financial readiness for the acquisition.

Negatives

• Mural Oncology plc's ordinary shares have been delisted from The Nasdaq Global Market, removing public trading access.
• The company intends to suspend its reporting obligations, reducing transparency for former public shareholders.
• Shareholders cease to have any rights as shareholders other than the right to receive the Scheme Consideration.

Risks

• The filing references general risks and uncertainties pertaining to Mural's business as described in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and definitive proxy statement, as well as XOMA Royalty's filings. No new specific risks are detailed in this 8-K.

Future Outlook

The company expects the distribution of cash consideration to Scheme Shareholders to commence as soon as practicable following the Effective Date, with completion by December 19, 2025. Mural also intends to file a Form 15 to suspend its reporting obligations under the Exchange Act.

Management Comments

• The directors of Mural accept responsibility for the information contained in this announcement.
• These resignations were tendered in connection with the Acquisition and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company’s operations, policies or practices.

Industry Context

This announcement marks the successful completion of an acquisition in the oncology sector, a common trend in the biotechnology and pharmaceutical industries where smaller, specialized companies are acquired by larger entities or royalty corporations for their assets or pipelines. The delisting signifies the end of Mural Oncology as an independent publicly traded entity, integrating its assets and operations under XOMA Royalty's portfolio.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $2.035 cash per share, losing their equity stake and public trading access.
• Employees (former officers): Certain officers (Drs. Loew and Goodman, Mr. Cutler) were terminated and received severance payments.
• Management: New directors (Owen Hughes, Bradley Sitko) and a new CEO/Secretary (Owen Hughes) were appointed, replacing previous management.

Next Steps

• Distribution of cash consideration to Scheme Shareholders is expected to commence as soon as practicable, with completion by December 19, 2025.
• Nasdaq will file a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister Mural's Ordinary Shares.
• Mural intends to file a certification on Form 15 under the Exchange Act, requesting the suspension of its reporting obligations.

Key Dates

Recommendation

The acquisition has been completed, and shareholders are receiving a fixed cash consideration. There is no further trading in Mural Oncology shares, so a 'hold' recommendation reflects the finality of the transaction for existing shareholders awaiting payment. For new investors, the stock is no longer publicly traded.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Merger, Delisting, Scheme of Arrangement, Biotechnology, Oncology, Pharmaceuticals, Cash Consideration, SEC Filing, Form 8-K